Wikipedia

Yttrium (90Y) tacatuzumab tetraxetan

(redirected from Tacatuzumab tetraxetan)
Yttrium (90Y) tacatuzumab tetraxetan
Y-90 tacatuzumab tetraxetan structure.svg
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetα-fetoprotein
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6470H9971N1712O2007S4290Y
Molar mass145 kg/mol
(verify)

Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Counil
  2. ^ WHO Drug Information


This article is copied from an article on Wikipedia® - the free encyclopedia created and edited by its online user community. The text was not checked or edited by anyone on our staff. Although the vast majority of Wikipedia® encyclopedia articles provide accurate and timely information, please do not assume the accuracy of any particular article. This article is distributed under the terms of GNU Free Documentation License.

Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.